Phase 2 interim data: 100% tumor control, 88% vision preservation with bel-sar in early choroidal melanoma

Aura Biosciences, Inc.

100% tumor control (8/8) and 88% visual acuity preservation in patients receiving three cycles of bel-sar.
Statistically significant reduction in tumor growth rate: -0.289 mm/yr (p<0.0001) vs. each patient's documented rate.
No treatment-related SAEs; only mild anterior inflammation (Grade 1) in 20% of patients.
Company plans to initiate global Phase 3 trial enrollment this year based on these data.
Data presented at Macula Society 46th Annual Meeting with average 9 months follow-up.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.